Biosergen AB (BIOSGN.ST)

STO Healthcare Biotechnology

Biosergen AB operates in the Biotechnology industry of the Healthcare sector, headquartered in Solna, SE. The stock last traded at $0.53, up 0.00% on the session, giving a market capitalisation of $11.4M. Its beta of -0.02 implies it has historically moved less than the broad market.

Biosergen AB is a biopharmaceutical company specializing in the creation of antifungal medications. Its key development initiative is BSG005, an experimental antifungal drug candidate engineered to treat critical invasive fungal infections. The firm was established in 2004 and operates from its headquarters located in Solna, Sweden.

Biosergen AB is most often compared with the following Healthcare names: